Recent reports on NASH
Investigators have recently published ample data from several nonalcoholic steatohepatitis studies.
Here, Healio presents some of our current reports on those data and other new developments in the treatment of NASH and other liver diseases.
Q&A: Perspectum to evaluate imaging device as tool to identify NASH patients
Perspectum announced it will evaluate the use of LiverMultiScan as a diagnostic tool to identify eligible patients for enrollment into nonalcoholic steatohepatitis clinical trials. READ MORE
FDA issues complete response letter for obeticholic acid for fibrosis due to NASH
The FDA issued a complete response letter for the new drug application for obeticholic acid for treatment of fibrosis due to nonalcoholic steatohepatitis, according to a press release from Intercept Pharmaceutical Inc. READ MORE
Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial
Inventiva announced lanifibranor met primary and secondary endpoints in a phase 2b study for treatment of nonalcoholic steatohepatitis, according to speaker at an Inventiva web conference.
“Lanifibranor (1,200 mg) met the primary endpoints with a statistically significant reduction, after 6 months of treatment, of the Steatosis Activity Fibrosis score, which combines assessments of hepatocellular inflammation and ballooning, with no worsening in intention to treat and per protocol populations,” Pierre Broqua, PhD, chief scientific officer and cofounder of Inventiva, said during his presentation. READ MORE
Standard of care lifestyle counseling improves NASH, fibrosis in children with NAFLD
Standard of care lifestyle counseling correlated with improvements in nonalcoholic steatohepatitis or fibrosis in half of the children with nonalcoholic fatty liver, according to study results publish in Gastroenterology. READ MORE
Q&A: New tool may detect liver fat early on to prevent NASH, NAFLD
There are many people in the United States living with viral hepatitis, which can lead to liver health problems such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. READ MORE.
Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study
Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.
Durect announced positive data from a phase 1b trial of orally administered DUR-928 in NASH that demonstrated significant improvement in liver function. DUR-928 is reportedly the first endogenous epigenetic regulator that was clinically tested for difficult-to-treat liver diseases. READ MORE